A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)

Novartis Investigative Site, New York

Novartis Investigative Site, Erie

Novartis Investigative Site, Media

Novartis Investigative Site, Philadelphia

Novartis Investigative Site, Herndon

Novartis Investigative Site, Rockville

Novartis Investigative Site, Baltimore

Novartis Investigative Site, Baltimore

Novartis Investigative Site, Richmond

Novartis Investigative Site, Durham

Novartis Investigative Site, Charlotte

Novartis Investigative Site, Augusta

Novartis Investigative Site, Jacksonville

Novartis Investigative Site, Jacksonville

Novartis Investigative Site, Winter Park

Novartis Investigative Site, Orlando

Novartis Investigative Site, Miami

Novartis Investigative Site, Boca Raton

Novartis Investigative Site, Fort Myers

Novartis Investigative Site, Canton

Novartis Investigative Site, Okemos

Novartis Investigative Site, Waukesha

Novartis Investigative Site, Joliet

Novartis Investigative Site, St Louis

Novartis Investigative Site, Saint Charles

Novartis Investigative Site, Overland Park

Novartis Investigative Site, Lincoln

Novartis Investigative Site, Dallas

Novartis Investigative Site, Houston

Novartis Investigative Site, Friendswood

Novartis Investigative Site, Austin

Novartis Investigative Site, Colorado Springs

Novartis Investigative Site, Phoenix

Novartis Investigative Site, Torrance

Novartis Investigative Site, Pico Rivera

Novartis Investigative Site, Pasadena

Novartis Investigative Site, National City

Novartis Investigative Site, San Diego

Novartis Investigative Site, San Diego

Novartis Investigative Site, Redlands

Novartis Investigative Site, Orange

Novartis Investigative Site, Honolulu

Novartis Investigative Site, Corvallis

Novartis Investigative Site, Bellevue

Novartis Investigative Site, Fall River

Novartis Investigative Site, Willingboro

Novartis Investigative Site, Hato Rey